Financial Comparison: Cynapsus Therapeutics (CYNA) and Zosano Pharma (ZSAN)
Cynapsus Therapeutics (NASDAQ: CYNA) and Zosano Pharma (NASDAQ:ZSAN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
This table compares Cynapsus Therapeutics and Zosano Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Cynapsus Therapeutics and Zosano Pharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zosano Pharma has a consensus target price of $3.50, indicating a potential upside of 392.96%. Given Zosano Pharma’s higher probable upside, analysts clearly believe Zosano Pharma is more favorable than Cynapsus Therapeutics.
Valuation & Earnings
This table compares Cynapsus Therapeutics and Zosano Pharma’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Zosano Pharma||$310,000.00||90.38||-$29.83 million||($1.17)||-0.61|
Cynapsus Therapeutics has higher earnings, but lower revenue than Zosano Pharma. Zosano Pharma is trading at a lower price-to-earnings ratio than Cynapsus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
56.6% of Cynapsus Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Zosano Pharma shares are held by institutional investors. 3.0% of Zosano Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Cynapsus Therapeutics Company Profile
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.
Receive News & Ratings for Cynapsus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.